HealthLytix
is revolutionizing early disease detection

through cutting-edge advances in genetics & medical imaging


At HealthLytix, our mission is to improve screening and early detection of cancer and neurodegenerative disease so people can enjoy longer, healthier lives while reducing healthcare costs. To accomplish this, we’re developing new advances in genetics and medical imaging to create better clinical tools for risk prediction and early diagnosis.


HealthLytix
is revolutionizing early disease detection

through cutting-edge advances in genetics & medical imaging


At HealthLytix, our mission is to improve screening and early detection of cancer and neurodegenerative disease so people can enjoy longer, healthier lives while reducing healthcare costs. To accomplish this, we’re developing new advances in genetics and medical imaging to create better clinical tools for risk prediction and early diagnosis.



Source: Howlader N, Noone AM, Krapcho M, et al. (eds). SEER Cancer Statistics Review, 1975-2013, National Cancer Institute, Bethesda, MD, http://seer.cancer.gov/csr/1975_2013/, based on November 2015 SEER data submission, posted to the SEER website April 2016.

Genetics

Early detection starts with understanding individual risk.


Effective screening depends on clinicians knowing not only who to screen, but when to screen them. Screening too early can lead to unnecessary procedures and costs, while screening too late can result in poor outcomes.


Our personalized genetic tests support intelligent screening by going beyond traditional risk scores, which are static, to calculating an individual’s dynamic risk as a function of age, helping providers identify which patients may benefit from early screening and when. Powered by advanced AI and machine learning algorithms developed from proprietary clinical data for more than 3 million individuals, these genetics-based predictive models can also incorporate other clinical information to further refine risk and inform care pathway decisions.

Genetics

Early detection starts with understanding individual risk.


Effective screening depends on clinicians knowing not only who to screen, but when to screen them. Screening too early can lead to unnecessary procedures and costs, while screening too late can result in poor outcomes.


Our personalized genetic tests support intelligent screening by going beyond traditional risk scores, which are static, to calculating an individual’s dynamic risk as a function of age, helping providers identify which patients may benefit from early screening and when. Powered by advanced AI and machine learning algorithms developed from proprietary clinical data for more than 3 million individuals, these genetics-based predictive models can also incorporate other clinical information to further refine risk and inform care pathway decisions.

Imaging

Early detection depends on timely use of accurate diagnostic tools for at-risk individuals.


Our quantitative imaging solutions are designed to help physicians diagnose disease more accurately and confidently and to improve workflow efficiency. Using advanced AI and machine learning algorithms combined with proprietary biophysical models, we’ve developed novel imaging biomarkers and quantitative tools to support early detection and staging of cancer. Our imaging technologies are backed by more than 20 peer-reviewed publications across several different cancer types, including prostate, brain, and breast cancer.

Learn More

Imaging

Early detection depends on timely use of accurate diagnostic tools for at-risk individuals.


Our quantitative imaging solutions are designed to help physicians diagnose disease more accurately and confidently and to improve workflow efficiency. Using advanced AI and machine learning algorithms combined with proprietary biophysical models, we’ve developed novel imaging biomarkers and quantitative tools to support early detection and staging of cancer. Our imaging technologies are backed by more than 20 peer-reviewed publications across several different cancer types, including prostate, brain, and breast cancer.

Learn More

Platform

Patient analytics and reports are generated and accessed through our secure, cloud-based Physician Portal.


Our cloud-based platform hosts and deploys our genetics and imaging applications and provides integrative clinical decision support analytics. Using our user-friendly dashboard, clinicians can quickly, easily, and securely access their patient analytics and reports to inform clinical decision-making and support accurate, timely diagnosis.

Platform

Patient analytics and reports are generated and accessed through our secure, cloud-based Physician Portal.


Our cloud-based platform hosts and deploys our genetics and imaging applications and provides integrative clinical decision support analytics. Using our user-friendly dashboard, clinicians can quickly, easily, and securely access their patient analytics and reports to inform clinical decision-making and support accurate, timely diagnosis.

News


November 18, 2019

Christine Swisher, PhD, Joins HealthLytix as Director of Science & Engineering

Swisher is an expert in using AI and machine learning to integrate genetics, medical imaging, and clinical data to create cutting-edge healthcare solutions.
October 8, 2019

HealthLytix Featured on Sano Genetics Podcast

On this week's podcast from Sano Genetics, Renee George, PhD, bioinformatics data scientist at HealthLytix, discussed the genetics of late-onset Alzheimer's disease.
May 29, 2019

HealthLytix to Exhibit at ASNR, Promote CT CoPilot® Solution

CT CoPilot is a quantitative imaging tool that improves radiologist efficiency and clinical confidence when reading head CT exams.

Our Clinical & Research

Partners






Our Partners


Attending RSNA?

Visit HealthLytix, Booth #3672

South Hall, Level 3
McCormick Place, Chicago, IL


Learn about our new FDA-cleared imaging software, RSI-MRI+, which uses a patented advanced diffusion MRI technique, biophysical models, and AI to support improved prostate cancer detection and diagnosis.

Interested in scheduling a meeting? Contact Mark Wittenberg, Head of Business Development, at mark.wittenberg@healthlytix.com.